Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 9
FIT-HF Semaglutide Trial Protocol
FIT-HF will compare semaglutide with intensive diet-based weight loss in 100 adults with obesity and reduced-ejection-fraction heart failure.
GLP-1 Social Media Sourcing Survey
A 2026 survey tested which mock social posts shaped GLP-1 purchase choices. Its self-reported, online sample sets important limits on the findings.
Incretin Drugs for PCOS: 2026 Review
A 2026 review maps semaglutide, tirzepatide and retatrutide for PCOS, but reproductive evidence still trails weight-loss data.
Oral Obesity Drugs: 2026 Review
A German review compares oral semaglutide and orforglipron, while trial data show convenience does not remove efficacy or safety tradeoffs.
Semaglutide Blood Pressure Meta-analysis
A seven-trial meta-analysis found a modest systolic blood-pressure reduction with subcutaneous semaglutide versus placebo.
Semaglutide and Muscle Cells: New Study
A six-donor cell study found no direct muscle atrophy signal from semaglutide, but it cannot settle what happens in people over time.
Semaglutide Nanoparticles in Oral Cancer
A preclinical paper tested semaglutide-loaded nanoparticles in oral cancer models, but it provides no evidence for cancer treatment in people.
Tirzepatide and Gastric Remnant Necrosis
A case report raises tirzepatide as one possible contributor to gastric remnant necrosis after bypass, but it cannot establish causality.
Tirzepatide and Sleep Apnea Evidence
A 2026 narrative review links tirzepatide with respiratory and metabolic changes in sleep apnea. The underlying trials define what is established.
Semaglutide import rules in Denmark
Denmark permits some personal semaglutide imports, but lawful sale, exact product identity and personal-use records still matter.
GLP-1 drugs and bone: what 12 trials show
A 2026 meta-analysis found a small lumbar-spine signal but no eligible tirzepatide or semaglutide 2.4 mg bone trials.
LEAP-BED Semaglutide and Tirzepatide Pilot
A 41-person prospective pilot found an early symptom signal, but its small nonrandomized comparison cannot establish treatment efficacy.